Goldman Sachs’s Elicio Therapeutics ELTX Stock Holding History

Goldman Sachs’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-57,818	Closed	-$618K	–	6690
2026 Q1	$618K	Buy	+57,818	New	+$558K	﹤0.01%	5463

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Goldman Sachs's ELTX Position: Q2 2026 in Review

Goldman Sachs sold out of Elicio Therapeutics (ELTX) in Q2 2026, closing a stake of 57,818 shares — an estimated $618K sold.

Goldman Sachs first reported a position in ELTX in Q1 2026 and held it in 1 quarter. The position peaked at $618K in Q1 2026. 48 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

Goldman Sachs reported no remaining Elicio Therapeutics position as of Q2 2026 after selling out during the quarter.
Goldman Sachs sold 57,818 Elicio Therapeutics shares in Q2 2026, an estimated $618K.
Goldman Sachs first reported a position in Elicio Therapeutics in Q1 2026 and held it in 1 quarter.
Goldman Sachs's Elicio Therapeutics position peaked at $618K in Q1 2026.
48 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.